abraxane

Key facts

Mechanism of action

Tubulin inhibitor

Primary target: Tubulin

Approval history

1. Abraxane /ml powder for dispersion for infusion. for metastatic NSCLC patients Phase 3 · Telethon Foundation · metastatic NSCLC patients
2. BNT327-05 Phase 3 · BioNTech SE · First line triple-negative breast cancer (TNBC)
3. BO42864 Phase 3 · HOFFMANN-LA ROCHE · RET fusion−positive, metastatic Non-Small Cell Lung Cancer
4. CORT125134-556 Phase 3 · CORCEPT THERAPEUTICS · Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian,
5. D-US-60010-001 Phase 3 · Ipsen · Metastatic Pancreatic Adenocarcinoma
6. D702BC00001 Phase 3 · AstraZeneca · Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors
7. D9670C00001 Phase 3 · AstraZeneca · HER2-Low, Hormone Receptor Positive Breast Cancer which has
8. GO40241 Phase 3 · HOFFMANN-LA ROCHE · Early-Stage Resectable Non-small cell lung cancer (NSCLC)

1. brentuximab vedotin Antineoplastic and immunomodulating agents (L01)
2. cabazitaxel Antineoplastic and immunomodulating agents (L01)
3. colchicine Musculo-skeletal system (M04)
4. docetaxel Antineoplastic and immunomodulating agents (L01)
5. paclitaxel Antineoplastic and immunomodulating agents (L01)
6. vincristine sulfate Tubulin inhibitor

Frequently asked questions